Enfortumab vedotin ejfv
Medical Oncology
Astellas Pharma Incantibody_drug_conjugatePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Medical Oncology cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Eisai Inc. | Phase 1/2 | B |
Itraconazole Boehringer Ingelheim | Phase 1 | B |
Bay 1000394 Dana-Farber Cancer Institute | Phase 2 | CCC |
bay1217389 Bayer | Phase 1 | CC |
BAY1161909 Bayer | Phase 1 | CC |
bay1143269 Bayer | Phase 1 | CC |
bay1187982 Bayer | Phase 1 | CC |
Same molecule, other indications
Enfortumab vedotin ejfv is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →